论文部分内容阅读
加拿大卫生部告知消费者使用抗抑郁药奈法唑酮有严重肝损伤的危险。在加拿大，奈法唑酮以Serzone，Lin-nefazodone和Apo-nefazodone的商品名销售。该药物是用于抑郁治疗的一大类处方药之一。1994年，奈法唑酮在加拿大上市。在全球上市后的使用过程中发现，奈法唑酮与黄疸/肝炎
Health Canada advised consumers that the use of the antidepressant nefazodone poses a serious risk of liver damage. Nefazodone is marketed under the trade names Serzone, Lin-nefazodone and Apo-nefazodone in Canada. The drug is one of a broad class of prescription drugs for depression treatment. Nefazodone was listed in Canada in 1994. The use of nefazodone and jaundice / hepatitis was found during the global market